摘要：【中文】本发明涉及合成黄芩素和野黄芩素的微生物、其制备方法及其应用。本发明人通过基因工程的方法对宿主细胞的异源代谢途径进行改造，获得了高产黄芩素和野黄芩素的工程菌株。本发明还提供了利用所述工程菌株生产黄芩素和野黄芩素的工艺。 【EN】The invention relates to a microorganism for synthesizing baicalein and scutellarein, a preparation method and application thereof. The present inventors obtained high-yield baicalein and scutellarein engineering strains by modifying the heterologous metabolic pathway of host cells through a genetic engineering method. The invention also provides a process for producing baicalein and scutellarein by using the engineering strain.

摘要：【中文】本发明公开了黄酮碳苷单体化合物牡荆苷、异牡荆苷、荭草苷、异荭草苷在制备镇痛药物和促伤口愈合药物中的应用，其中异荭草苷的镇痛活性显著强于阿司匹林和罗通定，荭草苷与牡荆苷具有较强的促伤口愈合的作用。 【EN】The invention discloses application of vitexin, isovitexin, orientin and isoorientin serving as flavone C-glycoside monomer compounds in preparation of analgesic drugs and drugs for promoting wound healing, wherein the analgesic activity of the isoorientin is remarkably higher than that of aspirin and rotundine, and the orientin and the vitexin have stronger effects of promoting wound healing.

摘要：【中文】本发明公开了一种木糖阿拉伯糖共利用的酿酒酵母菌株及其构建方法，该菌株的基因组上整合了多拷贝的阿拉伯糖代谢基因表达盒，所述基因表达盒包含基因araA、araB、araD、GAL2和STP2。本发明的的酿酒酵母菌能够用于代谢木质纤维素原料中的木糖和阿拉伯糖而生成乙醇。 【EN】The invention discloses a saccharomyces cerevisiae strain with xylose and arabinose co-utilization and a construction method thereof, wherein a multi-copy arabinose metabolic gene expression box is integrated on the genome of the strain, and the gene expression box comprises genes araA, araB, araD, GAL2 and STP 2. The saccharomyces cerevisiae of the invention can be used for metabolizing xylose and arabinose in the lignocellulose raw material to generate ethanol.

摘要：【中文】本发明公开了一种lacUV5启动子突变体SEQ ID NO:1，其能够促进T7RNA聚合酶的表达，提高外源重组蛋白质在大肠杆菌中的表达水平，延长表达时间，从而增加重组蛋白质生产量，具有商业应用前景。 【EN】The invention discloses a lacUV5 promoter mutant SEQ ID NO. 1, which can promote the expression of T7RNA polymerase, improve the expression level of exogenous recombinant protein in escherichia coli, prolong the expression time, increase the production of recombinant protein and has commercial application prospect.

摘要：【中文】本发明提供了一种草酸代谢相关酶及其在草酸降解中的应用，具体地，通过调控植物中草酸代谢相关酶基因或其蛋白的表达或活性，可显著调控植物中的草酸含量。 【EN】The invention provides an oxalate metabolism related enzyme and application thereof in oxalate degradation, and particularly can obviously regulate and control the oxalate content in plants by regulating and controlling the expression or activity of oxalate metabolism related enzyme genes or proteins thereof in the plants.

摘要：【中文】本发明提供一种抗体进化方法，所述抗体进化方法包含以下步骤：1）提供单碱基基因编辑系统，所述单碱基基因编辑系统可形成单碱基基因编辑复合体，所述单碱基基因编辑复合体包括dCas9酶、sgRNA、MS2胞嘧啶脱氨酶融合蛋白，所述sgRNA靶向待进化抗体的可变区基因；2）利用1）中所述的单碱基基因编辑系统对待进化抗体的可变区基因进行碱基突变，表达突变抗体，获得突变抗体库；3）筛选并富集高亲和力抗体。本发明通过对细胞进行基因编辑，真正实现了抗体基因的定范围自主突变。并通过结合后续的流式分选技术，从而定向选择抗体的进化，提高抗体进化效率。 【EN】The invention provides an antibody evolution method, which comprises the following steps: 1) providing a single base gene editing system that can form a single base gene editing complex comprising dCas9 enzyme, sgRNA, MS2 cytosine deaminase fusion protein, the sgRNA targeting a variable region gene of an antibody to be evolved; 2) carrying out base mutation on the variable region gene of the antibody to be evolved by using the single base gene editing system in 1) to express a mutant antibody and obtain a mutant antibody library; 3) high affinity antibodies were screened and enriched. The invention truly realizes the fixed-range autonomous mutation of the antibody gene by gene editing of cells. And the subsequent flow sorting technology is combined, so that the evolution of the antibody is directionally selected, and the evolution efficiency of the antibody is improved.

摘要：【中文】本发明提供了一种基于靶向组织微环境中衰老细胞的抗衰老药物D/A及其应用。将达沙替尼与阿司匹林联合应用，对于下调或清除机体衰老细胞具有极其优异的效果，从而可应用于清除组织微环境中的损伤细胞如化疗或辐射治疗后的受损细胞，也可应用于清除随年龄增长而自然衰老的细胞，从而延长机体的生存时间。 【EN】The invention provides an anti-aging drug D/A based on aged cells in a targeted tissue microenvironment and application thereof. The combination application of dasatinib and aspirin has extremely excellent effect on down-regulating or eliminating aged cells of an organism, so that the dasatinib and the aspirin can be applied to eliminating damaged cells in a tissue microenvironment, such as damaged cells after chemotherapy or radiation therapy, and can also be applied to eliminating naturally aged cells with the increase of age, thereby prolonging the survival time of the organism.

摘要：【中文】本发明提供了具有靶向组织微环境中衰老细胞作用的抗衰老药物D/S及其应用。将达沙替尼与SRT2104联合应用，对于下调或清除机体衰老细胞具有极其优异的效果，从而可应用于清除组织微环境中的损伤细胞如化疗或辐射治疗后的受损细胞，也可应用于清除随年龄增长而自然衰老的细胞，从而延长机体的生存时间。 【EN】The invention provides an anti-aging drug D/S with the function of targeting aging cells in a tissue microenvironment and application thereof. The combination application of dasatinib and SRT2104 has excellent effect of reducing or eliminating aged cells of organism, so that the dasatinib and SRT2104 can be used for eliminating damaged cells in tissue microenvironment, such as damaged cells after chemotherapy or radiation therapy, and can also be used for eliminating naturally aged cells with age, thereby prolonging the survival time of organism.

摘要：【中文】本发明涉及调节植物类黄酮合成及紫外抗性的基因及其应用。首次研究及揭示了油菜素甾醇信号通路对植物体内类黄酮合成以及植物对紫外线的抗性的影响及其分子机制。油菜素甾醇信号通路，特别是其中的转录因子BES1，其能够负调控MYB转录因子，在此基础上调控植物体内类黄酮合成，并进而调控植物对紫外线的抗性。 【EN】The invention relates to a gene for regulating plant flavonoid synthesis and ultraviolet resistance and application thereof. The first research and the disclosure of the influence of brassinosteroid signal path on the synthesis of flavonoid in plants and the resistance of plants to ultraviolet rays and the molecular mechanism thereof. Brassinosteroid signalling pathways, particularly the transcription factor BES1 therein, are capable of negatively regulating MYB transcription factors, and on the basis of this regulate flavonoid synthesis in plants, and thus the resistance of plants to ultraviolet light.

摘要：【中文】本发明涉及吲哚满酮衍生物在治疗肥胖及肥胖相关的疾病中的应用。更具体而言，本发明涉及下式I所示的吲哚满酮衍生物或其药学上可接受的盐在制备治疗或预防肥胖及肥胖相关的疾病的药物中的应用，式中各基团如文中所定义。 【EN】The present invention relates to the use of indolinone derivatives in the treatment of obesity and obesity related diseases. More particularly, the invention relates to the use of indolinone derivatives of formula I or pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prevention of obesity and obesity related diseases, wherein each group is as defined herein.